Pembrolizumab with carboplatin and paclitaxel for untreated advanced or recurrent endometrial cancer [ID6381] Draft guidance Technology appraisal guidance 14 April 2025 Natalizumab (originator and ...

To declare any new board interests and executive team interests, and consider any conflicts of interest specific to the meeting. Minutes of the last board meeting (Word) To approve the minutes of the ...

The treatment, called relugolix–estradiol–norethisterone (also known as relugolix combination therapy or Ryeqo), works by blocking specific hormones that contribute to endometriosis, while also ...

more consistent monitoring across healthcare settings. Our draft quality standard, published today for consultation, aims to identify people at risk of weight-related complications earlier so they can ...

In final draft guidance published today, we have recommended leniolisib (also called Joenja and made by Pharming) for treating activated phosphoinositide 3-kinase delta syndrome (APDS), an ultra-rare ...

Suggested remit: To appraise the clinical and cost effectiveness of daratumumab with bortezomib, lenalidomide and dexamethasone within its marketing authorisation for untreated multiple myeloma when ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee A. Committee members are asked to declare any interests in the technology being ...

A list of downloadable documents created during development.

A list of downloadable documents created during development.

NICE is unable to make a recommendation about the use in the NHS of atezolizumab (Tecentriq) for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is ...